Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.12 EUR | -1.99% | -4.89% | -11.63% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 25.9 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.63% | 11.04B | A- | ||
+24.67% | 89.29B | C+ | ||
-23.73% | 76.62B | B- | ||
+3.24% | 26.87B | C+ | ||
-12.06% | 16.56B | B | ||
-0.02% | 15.39B | A- | ||
+82.63% | 13.62B | C+ | ||
+75.93% | 13.61B | C- | ||
-24.56% | 12.67B | - | - | |
+23.23% | 12.59B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERF Stock
- Ratings Eurofins Scientific SE